Phytocannabinoid–Receptor Binding Explained

The lock-and-key problem (it's messier than that)

Receptor pharmacology gets described as a "lock and key" model in every first-year biochem textbook, and I spent most of my undergrad at the University of Melbourne accepting that metaphor without complaint. Then I started working through the primary literature on cannabinoid receptors and realised the metaphor flatters the situation considerably. The keys bend. The locks shift shape. Some molecules walk in through the back door.

That's what makes phytocannabinoid–receptor binding genuinely interesting, and also genuinely complicated to write about without overstating what the science actually supports.

A quick note before we go further: nothing in this article is a claim that any cannabinoid treats, prevents, or manages any condition. We're looking at molecular mechanisms and classification , the what and the how, not the should-you-take-it.

What a cannabinoid receptor actually is

The two best-characterised cannabinoid receptors are CB1 and CB2. Both are G protein-coupled receptors (GPCRs) , a class of transmembrane proteins that thread through the cell membrane seven times and transduce extracellular signals into intracellular responses. GPCRs are the largest family of drug targets in pharmacology, so this is not obscure territory; it just happens that the endocannabinoid system's version of them is unusually promiscuous in terms of what they'll bind.

CB1 is expressed densely in the central nervous system , the basal ganglia, cerebellum, hippocampus, cerebral cortex. CB2, initially characterised in immune tissues, is now confirmed in the CNS as well, though at lower densities. The endocannabinoid system runs on these receptors as part of a broader retrograde signalling network: endogenous ligands like anandamide and 2-AG are synthesised on demand and released from the postsynaptic neuron to modulate the presynaptic one. It runs backwards by design. That's the evolved system phytocannabinoids are interacting with; and they didn't evolve to interact with it. That overlap is pharmacologically accidental, and it matters for understanding what binding actually means.

How THC binds, and why "partial agonist" matters

THC is a partial agonist at both CB1 and CB2. It binds the orthosteric binding site, the same pocket endogenous ligands occupy; and activates downstream G-protein signalling, but not to the ceiling a full agonist would reach. The distinction between partial and full agonism is not just academic. Partial agonism means the ceiling effect limits maximal receptor activation, which has implications for both the pharmacological profile and the potential for receptor downregulation with repeated exposure.

At the structural level, THC fits the CB1 binding pocket largely because it's highly lipophilic and adopts a conformation that complements the hydrophobic interior of the receptor. Key residues, including phenylalanine at position 3.36 and tryptophan at 6.48, using Ballesteros–Weinstein numbering, make direct contact with THC's ring system. Mutational studies have confirmed that disrupting these residues significantly reduces binding affinity.

The partial agonism story gets even more layered when you factor in biased agonism: the hypothesis that different ligands can stabilise different receptor conformations and preferentially activate some downstream pathways over others. This is an active area of cannabinoid receptor research, and I want to be clear that biased agonism for most phytocannabinoids is still largely at the hypothesis stage; the in vitro data is intriguing, the in vivo picture is far less settled.

CBD's receptor profile, genuinely strange

If THC is the lock-and-key story's hero, cannabidiol is the plot twist that took decades to make sense of.

CBD has very low binding affinity at CB1 and CB2 orthosteric sites. Early radioligand binding studies suggested it barely registered. So for years the pharmacological mechanism was essentially a mystery, real effects were being observed in research models, but the classical cannabinoid receptor story didn't explain them.

What's emerged since is a picture of CBD as a highly promiscuous molecule with activity across a suite of non-CB1/CB2 targets. It acts as a negative allosteric modulator (NAM) at CB1; meaning it binds a separate site on the receptor and changes its shape in ways that reduce how effectively other agonists activate it. It also shows activity at TRPV1 (the capsaicin receptor, formally a transient receptor potential vanilloid channel), at 5-HT1A serotonin receptors, at GPR55, and at several others. The TRPV1 receptor interaction in particular has attracted significant research attention.

I'll be honest: the multi-target profile of CBD makes it harder to study cleanly, not easier. Every receptor interaction is a potential confound in any experiment that doesn't control for all of them. Researchers working in this space know this; popular reporting often doesn't reflect it.

Minor phytocannabinoids and their binding profiles

THC and CBD get the headlines, but cannabis produces over 100 identified phytocannabinoids. The binding data for most of them is sparse by comparison.

CBG (cannabigerol) shows partial agonism at CB1 and CB2, and also interacts with alpha-2 adrenoceptors and TRPV1. CBN (cannabinol), which forms as THC degrades, is a low-affinity partial agonist at CB1, significantly lower affinity than THC. CBC (cannabichromene) has very low binding affinity at CB1/CB2 but may interact with TRPA1 and TRPV1 channels. The data for many others, CBDA, CBGA, and various synthetic variants; is thinner still, and extrapolating from in vitro binding assays to any claim about function in a living system is a significant leap that the literature doesn't always make clearly enough.

The endocannabinoidome, the broader signalling network beyond classical CB1/CB2, adds further complexity. Some phytocannabinoids appear to interact with receptors and lipid mediator pathways that weren't on anyone's radar a decade ago.

Allosteric modulation; the back-door mechanism

Allosteric modulation deserves its own moment because it's frequently misunderstood.

When a molecule binds an allosteric site rather than the orthosteric site, it doesn't directly activate or block the receptor the way a classical agonist or antagonist does. Instead, it changes the receptor's shape in ways that alter how other ligands interact with it. A positive allosteric modulator (PAM) enhances another ligand's effect; a negative allosteric modulator (NAM) reduces it.

CBD's NAM activity at CB1 is the most discussed example in the cannabinoid literature. The implication, still largely a hypothesis in terms of its functional significance in vivo, is that CBD could modulate THC's CB1 activation without directly activating the receptor itself. Some researchers have speculated this contributes to the different subjective and physiological profiles of cannabis preparations with varying THC:CBD ratios. This feeds into discussions about the entourage effect; the idea that multiple cannabis constituents interact in ways that aren't predictable from each compound in isolation. That hypothesis has mechanistic plausibility but remains under-evidenced at the clinical level.

What binding affinity data can and can't tell you

Ki values, the dissociation constants from radioligand binding assays, are the standard way of expressing how tightly a molecule binds to a receptor. Lower Ki means higher affinity. THC has a Ki at CB1 of roughly 10–80 nM depending on the assay and preparation. Anandamide runs similar numbers. CBD's CB1 Ki is typically reported in the micromolar range, which is orders of magnitude less potent.

But Ki is not the whole story, and I'd argue this point is under-emphasised outside specialist pharmacology circles. Binding affinity tells you how tightly something binds; it doesn't tell you whether the receptor then activates a G-protein, recruits beta-arrestin, internalises, or does something else entirely. Functional assays; measuring cAMP levels, ERK phosphorylation, or receptor internalisation, layer on top of binding data and often complicate the picture.

Then there's pharmacokinetics, how a compound is absorbed, distributed, metabolised, and excreted. A molecule could have excellent receptor affinity and still produce a negligible effect in vivo if it's metabolised before it reaches the receptor, or if first-pass metabolism dramatically reduces its bioavailability. Bioavailability is the bridge between chemistry and physiology, and it's where a lot of in vitro excitement runs into real-world friction.

I killed another succulent this week, so trust me when I say: the conditions you study something in matter enormously. An in vitro assay is a controlled environment with none of the chaos of a living system. That's its value and its limitation simultaneously.

Where the research is heading

Cryo-EM and X-ray crystallography have now produced high-resolution structures of CB1 and CB2 in complex with various ligands, including THC. That structural data is letting researchers model the binding pocket with real precision and design experiments around specific receptor contacts rather than just correlating pharmacological effects. The 2016 and 2019 CB1 crystal structures (published in Cell and Nature, respectively) were landmarks for the field.

The CB2 receptor has attracted growing interest partly because of its expression in peripheral immune tissues; the hypothesis being that targeting CB2 might allow for receptor-specific pharmacology without the CNS activity associated with CB1. Whether that hypothesis translates into usable pharmacology is still very much an open question.

Understanding how phytocannabinoids bind receptors is a foundation for everything else in this field, formulation, regulation, research design. It's the layer beneath the layer. Getting it right matters.

Sources

• Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System, NCBI / NIH
• Crystal Structure of the Human Cannabinoid Receptor CB1; NCBI / NIH
• Cannabinoid Reference Standards, Therapeutic Goods Administration
• The Diverse CB1 and CB2 Receptor Pharmacology of Three Plant Cannabinoids: Δ9-Tetrahydrocannabinol, Cannabidiol and Δ9-Tetrahydrocannabivarin, NCBI / NIH

, Elise Tran, Science writer; cannabinoids & the ECS